Arctic Vision: Arctic Vision Starts China Phase III Trial of Farsightedness Therapy

Arctic Vision, a Shanghai ophthalmology company, enrolled the first patient in a China Phase III trial of a presbyopia (farsighted) therapy caused by loss of elasticity of the lens of the eye, usually in middle and old age. ARVN003 is a formulation of a well-known drug, pilocarpine, administered by the Optejet® microdosing dispenser. It is designed to provide short-term improvement in patients' vision. In 2020, Arctic Vision in-licensed two Optejet-based drugs from Eyenovia of New York City, ARN003 for farsightedness and ARVN002 for pediatric progressive nearsightedness. More details....Share this with colleagues: